Camasan vet 380/60/50 mg/ml Infusionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

camasan vet 380/60/50 mg/ml infusionsvätska, lösning

interchemie werken de adelaar eesti as - borsyra; kalciumglukonat (monohydrat); magnesiumkloridhexahydrat - infusionsvätska, lösning - 380/60/50 mg/ml - magnesiumkloridhexahydrat 60 mg aktiv substans; kalciumglukonat (monohydrat) 380 mg aktiv substans; borsyra 50 mg aktiv substans - får, nöt, svin

Calcibel 240/60/60 mg/ml Infusionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

calcibel 240/60/60 mg/ml infusionsvätska, lösning

bela-pharm gmbh & co. kg - borsyra; kalciumglukonat (monohydrat); magnesiumkloridhexahydrat - infusionsvätska, lösning - 240/60/60 mg/ml - borsyra 60 mg aktiv substans; magnesiumkloridhexahydrat 60 mg aktiv substans; kalciumglukonat (monohydrat) 240 mg aktiv substans - får, get, häst, nöt, svin

Izba Europeiska unionen - svenska - EMA (European Medicines Agency)

izba

novartis europharm limited - travoprost - ocular hypertension; glaucoma, open-angle - ophthalmologicals, antiglaucoma preparations and miotics - minskning av förhöjt intraokulärt tryck hos vuxna patienter med okulär hypertension eller öppenvinkelglaukom (se avsnitt 5. sänkning av förhöjt intraokulärt tryck på pediatriska patienter i åldern 3 år till < 18 år med okulär hypertension eller glaukom pediatriska.

Sitagliptin / Metformin hydrochloride Accord Europeiska unionen - svenska - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Sitagliptin / Metformin hydrochloride Sun Europeiska unionen - svenska - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Vildagliptin / Metformin hydrochloride Accord Europeiska unionen - svenska - EMA (European Medicines Agency)

vildagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 och 5. 1 för tillgänglig data på olika kombinationer).

Kalcium/Magnesium NET 180 mg / 43,7 mg Tuggtablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

kalcium/magnesium net 180 mg / 43,7 mg tuggtablett

evolan pharma ab - kalciumkarbonat; magnesiumhydroxid - tuggtablett - 180 mg / 43,7 mg - kalciumkarbonat 450,51 mg aktiv substans; magnesiumhydroxid 104,85 mg aktiv substans; sorbitol hjälpämne

balance 1.5 % glucose 1.75 mmol/l calcium Peritonealdialysvätska Sverige - svenska - Läkemedelsverket (Medical Products Agency)

balance 1.5 % glucose 1.75 mmol/l calcium peritonealdialysvätska

fresenius medical care deutschland gmbh - glukosmonohydrat; kalciumkloriddihydrat; magnesiumkloridhexahydrat; natriumklorid; natriumlaktatlösning - peritonealdialysvätska - natriumklorid 11,28 mg aktiv substans; kalciumkloriddihydrat 0,515 mg aktiv substans; magnesiumkloridhexahydrat 0,203 mg aktiv substans; natriumlaktatlösning 15,7 mg aktiv substans; glukosmonohydrat 33 mg aktiv substans - hypertona lösningar

balance 4.25 % glucose 1.75 mmol/l calcium Peritonealdialysvätska Sverige - svenska - Läkemedelsverket (Medical Products Agency)

balance 4.25 % glucose 1.75 mmol/l calcium peritonealdialysvätska

fresenius medical care deutschland gmbh - glukosmonohydrat; kalciumkloriddihydrat; magnesiumkloridhexahydrat; natriumklorid; natriumlaktatlösning - peritonealdialysvätska - kalciumkloriddihydrat 0,515 mg aktiv substans; magnesiumkloridhexahydrat 0,203 mg aktiv substans; glukosmonohydrat 93,5 mg aktiv substans; natriumlaktatlösning 15,7 mg aktiv substans; natriumklorid 11,28 mg aktiv substans - hypertona lösningar